Is Vir Biotechnology Stock a Buy?
Early in the coronavirus pandemic, Vir Biotechnology's (NASDAQ: VIR) stock rose -- literally and figuratively -- as it joined the list of biotechs looking for vaccines and therapies for the disease. But even though it found some success, with the pandemic now receding, investors have largely abandoned the stock. Vir's shares are down by 47% this year alone.
This could be a buying opportunity for long-term investors, but only if Vir has enough growth fuel left in the tank. Let's find out if that's the case.
Vir Biotechnology is an immunology company that seeks ways to treat and prevent infectious diseases. The company's antibody platform identifies rare antibodies from patients who have recovered from illnesses or are immune to them. It then uses these antibodies to create novel therapies. The pandemic was an opportunity for Vir to show its talents.
Source Fool.com
